Middle East and Africa Whole Exome Sequencing Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Middle East and Africa Whole Exome Sequencing Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Jun 2022
  • MEA
  • 350 Pages
  • No of Tables: 97
  • No of Figures: 40

Middle East & Africa Whole Exome Sequencing Market, By Component (Second-Generation Sequencing and Third-Generation Sequencing), Product and Service (Systems, Kits, and Services), Application (Drug Discovery and Development, Agriculture & Animal Research, Diagnostics, Personalized Medicine, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals and Clinics, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others), Industry Trends and Forecast to 2029.

Middle East and Africa Whole Exome Sequencing Market

Market Analysis and Insights

Middle East & Africa whole exome sequencing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.2% in the forecast period of 2022 to 2029. The increase in healthcare expenditure and funding are the major drivers which propelled the demand of the market in the forecast period.

Whole Exome Sequencing Market

Whole Exome Sequencing Market

However, side effects associated with the treatments of whole exome sequencing may hamper the future growth of whole exome sequencing market. Adoption of strategic alliances like partnerships and acquisitions by key market players act as opportunity for the growth of whole exome sequencing market.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Component (Second-Generation Sequencing and Third-Generation Sequencing), Product and Service (Systems, Kits, and Services), Application (Drug Discovery and Development, Agriculture & Animal Research, Diagnostics, Personalized Medicine, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals and Clinics, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others)

Countries Covered

Saudi Arabia, South Africa, UAE, Israel, Egypt, Rest of Middle East & Africa

Market Players Covered

Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.

Whole Exome Sequencing Market Definition

Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES. Whole-exome sequencing is a widely used whole exome sequencing method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing.

Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.

Middle East & Africa Whole Exome Sequencing Market Dynamics

Drivers

  • Increase in the adoption of next generation sequencing (NGS)

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

  • Growing usage of targeted sequencing methods

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

Restraint

  • Less comprehensive coverage of exons

All the exons are not comprehensively captured. The exon of importance may not be included in the current standard annotations of the human genome; and it is merely arduous to cover 100% of the exome with the current WES technology. Consequently, disease-causing variants in these “missed” exons go undetected.

WES has low sensitivity for structural variations, hence detection is limited. Nonetheless some CNVs, including indels and duplications, can be detected by WES, the technical limitation implies that others are likely missed

Opportunity

  • Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

  • Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.

Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.

Post COVID-19 Impact on Whole Exome Sequencing Market

COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.

Recent Development

  • In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
  • In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.

Middle East & Africa Whole Exome Sequencing Market Segmentation

Middle East & Africa whole exome sequencing market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

  • Second-Generation Sequencing
  • Third-Generation Sequencing

On the basis of component, the Middle East & Africa whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.

Product and Services

  • Systems
  • Kits
  • Services

On the basis of product and service, the Middle East & Africa whole exome sequencing market is segmented into systems, kits and services.

Application

  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • Agriculture & Animal Research
  • Others

On the basis of application, the Middle East & Africa whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Clinical Laboratories
  • Others

On the basis of end user, the Middle East & Africa whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories and others.

Distribution Channel

  • Direct Trade
  • Retail sales
  • Others

Whole Exome Sequencing Market

On the basis of distribution channel, the Middle East & Africa whole exome sequencing market is segmented into direct trade, retail sales and others.

Whole Exome Sequencing Market Country Level Analysis

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.

The countries covered in the whole exome sequencing market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East & Africa.

South Africa is going to dominating in forecast period due to the Increase in acceptance of next generation sequencing methods for prediction, treatment. South Africa is expected to grow due to monitoring of diverse chronic diseases such as cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Whole exome sequencing market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding whole exome sequencing market.

Competitive Landscape and Whole Exome Sequencing Market Share Analysis

Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Whole exome sequencing market.

The major companies which are dealing in the s Whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRIAL INSIGHTS:

4.4 CONCLUSION

5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS

6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING

6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING

6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION

6.2 RESTRAINTS

6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS

6.2.2 CYBER SECURITY CONCERNS IN GENOMICS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFESSIONALS

6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING

7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT

7.1 OVERVIEW

7.2 SECOND-GENERATION SEQUENCING

7.2.1 SEQUENCING BY SYNTHESIS (SBS)

7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)

7.3 THIRD-GENERATION SEQUENCING

8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE

8.1 OVERVIEW

8.2 SYSTEMS

8.2.1 HISEQ SERIES

8.2.1.1 HISEQ 2500

8.2.1.2 HISEQ 1500

8.2.2 MISEQ SERIES

8.2.3 ION TORRENT PLATFORMS

8.2.3.1 ION PROTON

8.2.3.2 ION PGM

8.2.4 OTHERS

8.3 KITS

8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS

8.3.2 LIBRARY PREPARATION KITS

8.3.3 TARGET ENRICHMENT KITS

8.3.4 OTHERS

8.4 SERVICES

8.4.1 SEQUENCING SERVICES

8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES

8.4.3 OTHERS

9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 DRUG DISCOVERY AND DEVELOPMENT

9.3 AGRICULTURE & ANIMAL RESEARCH

9.4 DIAGNOSTICS

9.5 PERSONALIZED MEDICINE

9.6 OTHERS

10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS AND CLINICS

10.5 CLINICAL LABORATORIES

10.6 OTHERS

11 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TRADE

11.3 RETAIL SALES

11.4 OTHERS

12 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY REGION

12.1 MIDDLE EAST AND AFRICA

12.1.1 SOUTH AFRICA

12.1.2 SAUDI ARABIA

12.1.3 U.A.E

12.1.4 ISRAEL

12.1.5 EGYPT

12.1.6 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

14 COMPANY PROFILE

14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COM PANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 MERCK KGAA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COM PANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 EXODX (A PART OF BIO-TECHNE)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COM PANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COM PANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COM PANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 AZENTA US, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 BECKMAN COULTER, INC

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIONEER CORPORATION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CD GENOMICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 CEGAT GMBH

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 EUROFINS SCIENTIFIC

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENTS

14.12 GENEDX, LLC

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GENEFIRST LIMITED.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 ILLUMINA, INC

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 INTEGRATED DNA TECHNOLOGIES, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 MERIDIAN BIOSCIENCE, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 PSOMAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 QIAGEN

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

14.19 SOPHIA GENETICS

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 TWIST BIOSCIENCE

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA THIRD-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA DRUG DISCOVERY AND DEVELOPMENT IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA AGRICULTURE & ANIMAL RESEARCH IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DIAGNOSTICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA PERSONALIZED MEDICINE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA ACADEMIC & RESEARCH INSTITUTES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA CLINICAL LABORATORIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA DIRECT TRADE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA RETAIL SALES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 43 SOUTH AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 54 SAUDI ARABIA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 55 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 U.A.E WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 65 U.A.E SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 66 U.A.E WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 67 U.A.E SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 68 U.A.E HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 69 U.A.E ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 70 U.A.E KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 71 U.A.E SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 72 U.A.E WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 U.A.E WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 U.A.E WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 76 ISRAEL SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 77 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 78 ISRAEL SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 79 ISRAEL HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 80 ISRAEL ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 81 ISRAEL KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 82 ISRAEL SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 83 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 86 EGYPT WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 87 EGYPT SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 88 EGYPT WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 89 EGYPT SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 90 EGYPT HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 91 EGYPT ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 92 EGYPT KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 93 EGYPT SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 94 EGYPT WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 EGYPT WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 EGYPT WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 REST OF MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET

FIGURE 15 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021

FIGURE 16 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)

FIGURE 18 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021

FIGURE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029)

FIGURE 22 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021

FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021

FIGURE 28 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 32 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 34 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 35 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021)

FIGURE 36 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021)

FIGURE 37 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029)

FIGURE 40 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

South Africa is the dominating region of the Middle East and Africa Whole Exome Sequencing Market.
The Middle East and Africa Whole Exome Sequencing Market growth rate will be 8.2% by 2029.
The Increase in the adoption of next generation sequencing (NGS) and Growing usage of targeted sequencing methods are the growth drivers of the Middle East and Africa Whole Exome Sequencing Market.
The component, product and service, application, end user and distribution channel are the factors on which the Middle East and Africa Whole Exome Sequencing Market research is based.
The major companies in the Middle East and Africa Whole Exome Sequencing Market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc.